Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low‐dose risperidone therapy

Vercammen, Laura; Buyse, Gunnar; Proost, J. E. F.; Hove, J. L. K. Van

doi:10.1023/a:1025916518457

Cited by 11 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While three of them developed NMS-like features (#2-4), one patient presented with predominantly SS-like features (#1). To our knowledge, NMS-like features have only been described in one previous patient with CLN3 disease [16] while there has been no prior description of SS-like features or other descriptions of rhabdomyolysis in CLN3 disease.…”

Section: Discussionmentioning

confidence: 91%

“…Another theory to explain the pathophysiological mechanisms behind NMS is the dopaminergic hypothesis given the relationship between NMS and dopamine agonistic drugs [19]. In comparison, adolescent patients with CLN3 have a pronounced loss of dopaminergic neurons [20] and it has been suggested that such a vulnerable dopaminergic system could predispose them to extrapyramidal side-effects including NMS [16]. A third possible cause of NMS could be a link to calcium-mediated disruption of the musculoskeletal system similar to malignant hyperthermia [21].…”

Section: Discussionmentioning

confidence: 99%

“…NMS has previously been described in a female with CLN3 disease and in a female with adult onset NCL of unknown genetic cause [15,16]. The aims of this study were to describe the occurrence of drug-induced hyperthermia in pediatric patients with CLN3 disease from West and South Sweden and to delineate the range of associated clinical features.…”

Section: Introductionmentioning

confidence: 96%

See 2 more Smart Citations

Drug-induced hyperthermia with rhabdomyolysis in CLN3 disease

Savvidou

Jennions

Wikström

et al. 2022

European Journal of Paediatric Neurology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Drug-induced hyperthermia with rhabdomyolysis in CLN3 disease

Savvidou

Jennions

Wikström

et al. 2022

European Journal of Paediatric Neurology

View full text Add to dashboard Cite

“…Delusions, as well as visual and auditory hallucinations, have been reported . The association of psychosis with dementia is common, and a propensity toward neuroleptic malignant syndrome has been reported …”

Section: Resultsmentioning

confidence: 99%

Nosology and Phenomenology of Psychosis in Movement Disorders

Rossi

Farcy

Starkstein

et al. 2020

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background Background: Psychotic symptoms, such as delusions and hallucinations, are part of the clinical picture of several conditions presenting movement disorders. Phenomenology and epidemiology of psychosis in Parkinson's disease have received wide attention; however, the presence of psychosis in other movement disorders is, comparatively, less well known. Objectives Objectives: To review psychotic symptoms present in different movement disorders. Methods Methods: A comprehensive and structured literature search was performed to identify and analyze data on patients with movement disorders and comorbid psychosis.

show abstract

The neuropsychiatry of inborn errors of metabolism

Walterfang

Bonnot

Mocellin

et al. 2013

J of Inher Metab Disea

View full text Add to dashboard Cite

A number of metabolic disorders that affect the central nervous system can present in childhood, adolescence or adulthood as a phenocopy of a major psychiatric syndrome such as psychosis, depression, anxiety or mania. An understanding and awareness of secondary syndromes in metabolic disorders is of great importance as it can lead to the early diagnosis of such disorders. Many of these metabolic disorders are progressive and may have illness-modifying treatments available. Earlier diagnosis may prevent or delay damage to the central nervous system and allow for the institution of appropriate treatment and family and genetic counselling. Metabolic disorders appear to result in neuropsychiatric illness either through disruption of late neurodevelopmental processes (metachromatic leukodystrophy, adrenoleukodystrophy, GM2 gangliosidosis, Niemann-Pick type C, cerebrotendinous xanthomatosis, neuronal ceroid lipofuscinosis, and alpha mannosidosis) or via chronic or acute disruption of excitatory/inhibitory or monoaminergic neurotransmitter systems (acute intermittent porphyria, maple syrup urine disease, urea cycle disorders, phenylketonuria and disorders of homocysteine metabolism). In this manuscript we review the evidence for neuropsychiatric illness in major metabolic disorders and discuss the possible models for how these disorders result in psychiatric symptoms. Treatment considerations are discussed, including treatment resistance, the increased propensity for side-effects and the possibility of some treatments worsening the underlying disorder.

show abstract

Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low‐dose risperidone therapy

Cited by 11 publications

References 4 publications

Drug-induced hyperthermia with rhabdomyolysis in CLN3 disease

Drug-induced hyperthermia with rhabdomyolysis in CLN3 disease

Nosology and Phenomenology of Psychosis in Movement Disorders

The neuropsychiatry of inborn errors of metabolism

Contact Info

Product

Resources

About